Existing backers including GlaxoSmithKline and Roche were joined by Pfizer and Woodford Patient Capital for the Cambridge spinout's series C round.
UK-based drug developer Mission Therapeutics raised £60m ($86m) in a series C round yesterday backed by investors including pharmaceutical firms Roche, Pfizer and GlaxoSmithKline.
The three corporates invested through their respective corporate venturing units Roche Venture Fund, Pfizer Venture Investments and SR One.
The round was led by technology transfer firm Imperial Innovations and also featured Woodford Patient Capital Trust, a fund aimed at university spinouts, and venture capital firm Sofinnova Partners.
Mission Therapeutics was spun out of Cambridge University…
